Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 167   

Articles published

AZN 4,880.50 -71.50 (-1.44%)
price chart
AstraZeneca Plc (NYSE:AZN) Sends Synairgen Plummeting On Ditching Asthma Drug ...
Synairgen felt the full wrath of the market on AstraZeneca Plc (NYSE:AZN) pulling the plug on a phase II trial of its drug targeting severe Asthma.
Investor Market Move: Cypress Asset Management INC Holding in Astrazeneca ...  Chester News
what are Analysts report about: AstraZeneca PLC (NYSE:AZN)  News Oracle
AstraZeneca plc (AZN) Given a GBX 4000 Price Target by Goldman Sachs Group Inc ...
AstraZeneca plc logo AstraZeneca plc (LON:AZN) has been assigned a GBX 4,000 ($48.75) target price by equities research analysts at Goldman Sachs Group Inc. in a report released on Wednesday.
AstraZeneca plc (AZN) PT Set at GBX 5333 by Sanford C. Bernstein  Community Financial News
AstraZeneca plc (AZN) Given a GBX 4000 Price Target at Goldman Sachs Group Inc.  BBNS
Revenue Estimates Analysis of: AstraZeneca PLC (NYSE:AZN)
AstraZeneca PLC (NYSE:AZN) reported the earnings of $0.83/Share in the last quarter where the estimated EPS by analysts was $0.76/share.
AstraZeneca PLC's (AZN): Monitor the Current Moves  Hot Stocks Point
Stock Worth Mentioning: AstraZeneca plc (ADR) Just Recorded A Sigfniciant ...  Press Telegraph
AstraZeneca Plc (NYSE:AZN) Offloads Two Diabetes Drugs to Focus on Core ...
AstraZeneca Plc (NYSE:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary of 3SBio, in China.
AstraZeneca plc 21.2% Potential Upside Indicated by Jefferies International  DirectorsTalk Interviews
Synairgen slumps by a third as AstraZeneca ditches asthma drug study
Synairgen Plc said its partner AstraZeneca Plc stopped a mid-stage study for testing Synairgen's drug candidate as a potential treatment for severe asthma, putting the brakes on the lead product in Synairgen's pipeline.
Synairgen: AstraZeneca stopped asthma drug trial  MarketWatch
AstraZeneca licenses out Crohn's antibody for US$250mln
AstraZeneca PLC's (LON:AZN) biologics research and development arm, MedImmune, has entered into a licensing agreement with Allergan PLC for the global rights to synthetic antibody MEDI2070.
AstraZeneca plc (ADR) (NYSE:AZN) Inks License Deal With Allergan plc ...  TCC
AstraZeneca signs $1.5 bln deal with Allergan  MarketWatch
Facebook Founder's Science Group Hires AstraZeneca Board Member
The Chan Zuckerberg Initiative, Facebook Inc. founder Mark Zuckerberg's $3 billion effort to find cures for diseases, hired AstraZeneca Plc board member Cornelia Bargmann as president of its science arm. Bargmann, an American neurobiologist, will step ...
AstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies
For AstraZeneca Plc, when it comes to beating cancer there's strength in numbers. The drugmaker is combining two medicines to overcome lung cancer's defenses against an immune system attack, an approach that became more attractive after rivals' studies ...
Wil AstraZeneca plc (ADR) (AZN) Compete in Lung Cancer Treatment?  The Voice Observer
AstraZeneca plc 20.6% Potential Decrease Indicated by Credit Suisse
AstraZeneca plc with EPIC/TICKER LON:AZN had its stock rating noted as 'Reiterates' with the recommendation being set at 'UNDERPERFORM' this morning by analysts at Credit Suisse.
AstraZeneca plc (AZN) Rating Reiterated by JPMorgan Chase & Co.  Community Financial News
Recent analysts Ratings: AstraZeneca PLC (NYSE:AZN)
AstraZeneca PLC (NYSE:AZN) reported its last earnings on Jun 16. The company reported the earnings of $0.83/Share in the last quarter where the estimated EPS by analysts was $0.76/share.
Stock to Watch: AstraZeneca plc (NYSE:AZN)  Post Registrar
AstraZeneca plc (AZN) Earns Buy Rating from Deutsche Bank AG  The Cerbat Gem